BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 15668193)

  • 1. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
    Eisses MJ; Velan T; Aldea GS; Chandler WL
    Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.
    Chandler WL; Velan T
    Thromb Res; 2003; 112(3):185-92. PubMed ID: 14967416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin.
    Ray MJ; Marsh NA
    Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Effect of aprotinin.
    Mannucci L; Gerometta PS; Mussoni L; Antona C; Parolari A; Salvi L; Biglioli P; Tremoli E
    Thromb Haemost; 1995 Mar; 73(3):356-61. PubMed ID: 7545317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmin generation and D-dimer formation during cardiopulmonary bypass.
    Chandler WL; Velan T
    Blood Coagul Fibrinolysis; 2004 Oct; 15(7):583-91. PubMed ID: 15389126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
    Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
    Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
    Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
    Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass.
    Ray MJ; Marsh NA; Hawson GA
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):679-85. PubMed ID: 7865673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.
    Eisses MJ; Chandler WL
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):53-9. PubMed ID: 18249331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss.
    Mastroroberto P; Chello M; Zofrea S; Marchese AR
    Eur J Cardiothorac Surg; 1995; 9(3):143-5. PubMed ID: 7540397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass.
    Chandler WL
    J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):459-67. PubMed ID: 16085250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets and soluble fibrin promote plasminogen activation causing downregulation of platelet glycoprotein Ib/IX complexes: protection by aprotinin.
    de Haan J; van Oeveren W
    Thromb Res; 1998 Nov; 92(4):171-9. PubMed ID: 9840026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
    Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
    Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.